Related Experiment Videos
Developing treatments for inborn errors: incentives available to the clinician
1FDA Office of Orphan Products Development, Food and Drug Administration, Rockville, MD 20857, USA. mhaffner@oc.fda.gov
Molecular Genetics and Metabolism
|March 31, 2004
Summary
The US Orphan Drug Act (ODA) incentivizes rare disease drug development, benefiting patients with inborn errors of metabolism (IEM). This legislation has spurred global efforts to treat rare conditions.
Area of Science:
- Biomedical Science
- Pharmacology
- Public Health Policy
Background:
- Inborn errors of metabolism (IEM) affect small populations, posing challenges for drug development.
- Growing concern exists for patients with inherited metabolic disorders globally.
- The US Orphan Drug Act (ODA) was enacted in 1983 to address the needs of rare disease patients.
Purpose of the Study:
- To analyze the impact of the US Orphan Drug Act (ODA) on the development of treatments for rare diseases.
- To examine the global influence of US orphan drug legislation.
- To highlight the importance of international collaboration in rare disease research.
Main Methods:
- Review of the US Orphan Drug Act (ODA) provisions and their economic incentives.
- Analysis of the historical impact of the ODA on drug approvals for rare diseases.
- Examination of subsequent international orphan drug legislation and policies.
Main Results:
- The ODA provides tax credits, grant funding, and marketing exclusivity for orphan drugs.
- US legislation has successfully encouraged the development of treatments for IEM.
- The ODA's success influenced the adoption of similar laws in Japan, Australia, and the EU.
Conclusions:
- Orphan drug legislation is crucial for addressing the unmet needs of patients with rare metabolic disorders.
- International cooperation is essential for overcoming financial barriers in rare disease drug development.
- Global support for rare disease research is vital for advancing treatments worldwide.